 Results from the phase 3 INFRONT-3 study using AL001 for the treatment of patients with Frontotemporal dementia are expected in 2023. Alector holds the potential to advance AL001 for both FTD-GRN and FTD-C9orf72 patients, plus several other neurological indications like Alzheimers Disease and Parkinsons Disease. 